Streamlining mavacamten treatment pathways: clinical and economic evaluation of point-of-care CYP2C19 genotyping

Clicks: 6
ID: 321066
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #17 of 20 articles by views in international journal of pharmacy practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Objectives To evaluate whether point-of-care (POC) CYP2C19 genotyping streamlines mavacamten initiation. Methods Pre–post service evaluation in a tertiary cardiology service; 10 consecutive patients underwent parallel laboratory and POC genotyping. Outcomes were concordance, turnaround time, number of appointments, patient preference, and costs. Key findings Concordance was 100%. Laboratory turnaround was 10 days; POC run time 63 min. Appointments fell from three to one. Costs decreased by £245.76 per patient for the health service and £118 for patients; break-even was about 3–4 patients per year. Conclusions POC genotyping is feasible, improves efficiency and experience, and offers a credible economic case.
Reference Key
openalex_W7168412118 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anisha Patel, Jessica Gadsby, Harshil Dhutia, Helen Knight, Julian Barwell, Hussain Mulla
Journal international journal of pharmacy practice
Year 2026
DOI
10.1093/ijpp/riag091
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.